Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults

Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults

The objective was to evaluate the effect of the consumption of dual probiotic strains containing Lactobacillus curvatus (L. curvatus) HY7601 and Lactobacillus plantarum (L. plantarum) KY1032 on weight loss, body adiposity and inflammatory markers including lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in overweight subjects.

A randomized, double-blind, placebo-controlled study was conducted on 120 subjects with age between 20 and 65 years, nondiabetic (fasting blood glucose <126 mg/dL and 2-hour blood glucose <200 mg/dL), and overweight (25 kg/m2 ≤ body mass index (BMI) < 30 kg/m2). Over a 12 week test period, the probiotic group consumed 2 g of powder twice a day containing L. curvatus HY7601 and L. plantarum KY1032, while the placebo group consumed the same product without probiotics for 12 weeks.

Inclusion Criteria:

• Age between 20 and 65 years
• Nondiabetic (fasting blood glucose <126 mg/dL and 2-hour blood glucose <200 mg/dL)
• Overweight (25 kg/m2 ≤ body mass index (BMI) < 30 kg/m2)

Exclusion Criteria:

• Constant consumption of any probiotics products within 1 month before screening
• Unstable body weight (body weight change > 1 kg within 3 months before screening)
• Hypertension
• Type 2 diabetes
• Cardiovascular disease
• Cerebrovascular disease
• Thyroid disease
• Dietary supplementation within 6 months before screening
• Pregnancy or breast-feeding
• Medication affecting body weight, energy expenditure, glucose control or antibiotic treatment within 3 months before screening
• Acute or chronic infections
• Liver disease
• Kidney disease
• Gastrointestinal disease
• Cancer
• Medication or alcohol abuse
• Any other acute or chronic disease requiring treatment